Antimicrobials Practice Questions

Q: A patient from a North-Eastern state was diagnosed to have an infection with P. Falciparum malaria. What is the most appropriate treatment for this patient?

Artemether plus lumefantrine. ***Artemether plus lumefantrine*** - Artemether-lumefantrine is the recommended first-line treatment for **uncomplicated P. falciparum malaria** in regions with known **chloroquine resistance**, such as North-Eastern India. - This combination therapy, an **Artemisinin-based Combination Therapy (ACT)**, is highly effective due to its rapid parasiticidal action and synergy. *Chloroquine* - Chloroquine resistance in **P. falciparum malaria** is widespread, particularly in many parts of India, including the North East. - Using chloroquine alone would likely lead to **treatment failure** and worsening of the patient's condition. *Mefloquine* - Mefloquine is an alternative treatment option, but it has significant drawbacks including **neuropsychiatric side effects** (e.g., anxiety, depression, hallucinations) and a long half-life. - It is often reserved for specific situations or as a second-line agent when ACTs are not available or contraindicated. *Sulfadoxine plus pyrimethamine* - **Sulfadoxine-pyrimethamine (SP)** is an older antimalarial drug combination that is not recommended as first-line treatment for **uncomplicated P. falciparum malaria** due to widespread **parasite resistance**. - While it was formerly used for prophylaxis and intermittent presumptive treatment, its efficacy against P. falciparum has significantly declined. *Quinine plus doxycycline* - **Quinine plus doxycycline** is an effective alternative for treating **P. falciparum malaria**, particularly in **severe cases** or when ACTs are contraindicated or unavailable. - However, it is **not the first-line treatment** for uncomplicated malaria due to longer treatment duration (7 days), more frequent dosing, and potential side effects (cinchonism, GI disturbances). - Requires adherence to a multi-day regimen, making ACTs more practical for uncomplicated cases.

Q: Which of the following chelating agents is indicated in iron overdose?

Desferrioxamine. ***Desferrioxamine*** - **Desferrioxamine** is a **chelate** formed by the bacterium *Streptomyces pilosus* that has a high affinity for **iron**. - It is currently the most commonly used chelating agent for **acute iron overdose** and **chronic iron overload** conditions like hemochromatosis or transfusional hemosiderosis. *BAL* - **BAL (dimercaprol)** is a chelating agent primarily used for poisoning with **arsenic**, **mercury**, and **gold**. - It works by forming stable cyclic compounds with these metals, facilitating their excretion. *Calcium Edetate* - **Calcium edetate (Calcium-EDTA)** is primarily used for **lead poisoning**. - It works by forming a stable, water-soluble complex with lead, which is then excreted by the kidneys. *DTPA* - **Diethylenetriamine pentaacetate (DTPA)** is a chelating agent primarily used for poisoning with **plutonium** and other **radioactive metals**. - It is not indicated for iron overdose. *Penicillamine* - **Penicillamine** is a chelating agent primarily used for **copper** overload (Wilson's disease) and can also be used for **lead** and **mercury** poisoning. - It is not effective for iron chelation in overdose situations.

Q: In which phase of clinical trials is drug dosing typically determined?

Phase 1. ***Phase 1*** - This phase involves a small group of **healthy volunteers** to assess the drug's safety, **pharmacokinetics (PK)**, and establish an initial dosing range. - The primary goal is to determine a **safe dosage level**, establish the **maximum tolerated dose (MTD)**, and identify potential side effects. - This is where drug dosing is **typically determined**. *Phase 0* - This is an exploratory phase involving **microdosing** studies with subtherapeutic doses. - The goal is to gather preliminary PK/PD data, but **not to determine therapeutic dosing**. *Phase 2* - This phase involves a larger group of **patients** with the condition to be treated. - The main goal is to evaluate the drug's **effectiveness** and further assess safety, but not primarily to determine initial dosing. *Phase 3* - This phase involves a large number of patients across multiple sites to confirm the drug's **efficacy** and monitor side effects in a broader population. - Dosing strategies have generally been established in earlier phases, and this phase primarily validates them. *Phase 4* - This phase occurs **after a drug has been approved** and marketed. - It involves ongoing surveillance to monitor long-term effects, collect additional information on safety, and identify new uses, but not initial dose determination.

Q: Which of the following drugs, when given with erythromycin, can cause QT prolongation and Torsades de Pointes?

Astemizole. ***Astemizole*** - **Astemizole** is a second-generation antihistamine that undergoes extensive metabolism by the **CYP3A4 enzyme**. - Concomitant use with **erythromycin**, a potent **CYP3A4 inhibitor**, significantly increases astemizole plasma concentrations, leading to **QT prolongation** and an elevated risk of **Torsades de Pointes**. *Cetirizine* - **Cetirizine** is another second-generation antihistamine that is primarily eliminated via **renal excretion** and does not undergo significant CYP450 metabolism. - Therefore, its co-administration with **erythromycin** does not typically lead to clinically significant drug interactions impacting cardiac repolarization. *Fexofenadine* - **Fexofenadine** is a second-generation antihistamine and active metabolite of terfenadine that is primarily eliminated via **biliary excretion** and has minimal hepatic metabolism. - While it is a substrate of **P-glycoprotein** (which can be inhibited by erythromycin), fexofenadine has a much safer cardiac profile and does not typically cause **QT prolongation** even with CYP3A4 inhibitors. *Loratadine* - **Loratadine** is a second-generation antihistamine that is metabolized by **CYP2D6** and **CYP3A4**, but its active metabolite, desloratadine, has a lower propensity for QT prolongation. - While erythromycin is a CYP3A4 inhibitor, the risk of **QT prolongation** with **loratadine** is generally considered much lower than with astemizole, even with concurrent use. *Promethazine* - **Promethazine** is a first-generation antihistamine and phenothiazine derivative that primarily acts as a **dopamine D2 receptor antagonist**. - While it can cause **QT prolongation** on its own at high doses, its metabolism is complex and not predominantly dependent on **CYP3A4** to the extent that interaction with **erythromycin** poses the same severe risk as with astemizole.

Q: Aprepitant is a drug used in the treatment of some cases of chemotherapy-induced nausea and vomiting. What is the mechanism of action of this drug?

NK1 antagonist. ***NK1 antagonist*** - **Aprepitant** is a selective, high-affinity antagonist of the **neurokinin 1 (NK1) receptor**, which is activated by **substance P**. - By blocking NK1 receptors in the brainstem's **vomiting center**, aprepitant prevents nausea and vomiting, especially in chemotherapy-induced cases. - Aprepitant is particularly effective for **acute and delayed** chemotherapy-induced nausea and vomiting (CINV). *NK3 antagonist* - While **neurokinin 3 (NK3) receptors** are present in the central nervous system, their specific role in chemotherapy-induced nausea and vomiting is less prominent. - Aprepitant does not primarily target NK3 receptors; its antiemetic action is mediated through NK1 blockade. *NK1 agonist* - An **NK1 agonist** would activate the NK1 receptor, potentially *inducing* nausea and vomiting, which is the opposite of the desired therapeutic effect of aprepitant. - Agonists are typically used to stimulate a receptor, not block it as is done with aprepitant. *NK2 antagonist* - **Neurokinin 2 (NK2) receptors** are also part of the tachykinin receptor family, but they are not the primary target for antiemetic drugs like aprepitant. - While NK2 receptors play roles in smooth muscle contraction and inflammation, blocking them is not the mechanism by which aprepitant prevents nausea and vomiting. - Aprepitant's antiemetic efficacy is specifically due to **NK1 receptor antagonism**. *NK2 agonist* - **Neurokinin 2 (NK2) receptors** are also part of the tachykinin receptor family, but they are not the primary target for antiemetic drugs like aprepitant. - Activating NK2 receptors would not provide the antiemetic effect seen with aprepitant, as NK1 receptor antagonism is crucial.

Q: Methotrexate use causes reduced synthesis of which of the following?

TMP. ***TMP (Thymidylate)*** - Methotrexate is a **folate analog** that inhibits **dihydrofolate reductase (DHFR)**, preventing the regeneration of tetrahydrofolate (THF) from dihydrofolate. - **Tetrahydrofolate** is essential for **thymidylate synthase**, which converts dUMP to **TMP (thymidylate)** - this is the **most directly and significantly affected** nucleotide synthesis pathway. - Reduced TMP synthesis leads to impaired DNA synthesis and is the **primary mechanism** of methotrexate's cytotoxic effects. *CMP (Cytidine monophosphate)* - CMP synthesis occurs via the **de novo pyrimidine pathway** starting from carbamoyl phosphate and aspartate, forming UMP, which is then converted to CMP. - This pathway **does not require tetrahydrofolate** cofactors, so methotrexate does not significantly affect CMP synthesis directly. *GMP (Guanosine monophosphate)* - GMP is a purine nucleotide whose synthesis **does require tetrahydrofolate** derivatives (N10-formyl-THF) at two steps in the de novo purine pathway. - However, the effect on GMP is **less direct and less pronounced** than on TMP synthesis, and cells can partially compensate through salvage pathways. *AMP (Adenosine monophosphate)* - AMP is also a purine nucleotide that requires **N10-formyl-THF** cofactors during de novo synthesis (same pathway branch point as GMP). - Like GMP, it is affected but **less directly than TMP**, and salvage pathways provide alternative synthesis routes. *UMP (Uridine monophosphate)* - UMP is synthesized through the **de novo pyrimidine pathway** which does not require folate cofactors. - Methotrexate does not inhibit the enzymes (carbamoyl phosphate synthetase II, aspartate transcarbamoylase, dihydroorotase, etc.) involved in UMP synthesis.

Question 1

A tourist with a travel history to India presents with complaints of abdominal pain and multiple episodes of watery diarrhea. He reports having food at a local restaurant the previous night. Which of the following antidiarrheal agents is used in this condition?

Accepted Answer

Rifaximin

Answer

Bismuth subsalicylate

Answer

Octreotide

Answer

Loperamide

Answer

Ciprofloxacin

Question 2

A patient from a North-Eastern state was diagnosed to have an infection with P. Falciparum malaria. What is the most appropriate treatment for this patient?

Accepted Answer

Artemether plus lumefantrine

Answer

Chloroquine

Answer

Mefloquine

Answer

Sulfadoxine plus pyrimethamine

Answer

Quinine plus doxycycline

Question 3

Which of the following chelating agents is indicated in iron overdose?

Accepted Answer

Desferrioxamine

Answer

BAL

Answer

Calcium Edetate

Answer

DTPA

Answer

Penicillamine

Question 4

An 18-year-old boy from Rajasthan weighing 50 kg is diagnosed with mixed P . vivax and P . falciparum malaria. What is the appropriate treatment regimen on day 2?

Accepted Answer

Artesunate 50 mg (4 tablets) + Sulfadoxine/ pyrimethamine ( 750/37.5 mg ) (2 tablets) + Primaquine 2.5 mg ( 6 tablets)

Answer

Artesunate 50 mg (4 tablets) + Primaquine 2.5 mg ( 6 tablets)

Answer

Artesunate 50 mg (4 tablets) + Primaquine 7.5 mg (6 tablets)

Answer

Artesunate 50 mg (4 tablets) + Sulfadoxine/ pyrimethamine ( 750/37.5 mg ) (2 tablets) + Primaquine 7.5 mg ( 6 tablets)

Answer

Artesunate 50 mg (4 tablets) only

Question 5

In which phase of clinical trials is drug dosing typically determined?

Accepted Answer

Phase 1

Answer

Phase 2

Answer

Phase 3

Answer

Phase 4

Answer

Phase 0

Question 6

Which of the following statements about Ciclesonide is incorrect?

Accepted Answer

Oral candidiasis is common with its use.

Answer

It is a prodrug activated by bronchial esterase.

Answer

It has comparable efficacy to other inhalational corticosteroids.

Answer

It has fewer side effects than other inhalational corticosteroids.

Answer

It has low systemic bioavailability due to extensive first-pass metabolism.

Question 7

Which of the following drugs, when given with erythromycin, can cause QT prolongation and Torsades de Pointes?

Accepted Answer

Astemizole

Answer

Cetirizine

Answer

Loratadine

Answer

Promethazine

Answer

Fexofenadine

Question 8

Which of the following is an inclusion criterion for the shorter bedaquiline regimen in the treatment of tuberculosis?

Accepted Answer

Rifampicin-resistant but fluoroquinolone-sensitive TB

Answer

Extrapulmonary TB like Tubercular meningitis

Answer

Rifampicin resistance with both KatG and inhA mutation

Answer

Rifampicin-sensitive TB

Answer

Extensively drug-resistant TB (XDR-TB)

Question 9

Aprepitant is a drug used in the treatment of some cases of chemotherapy-induced nausea and vomiting. What is the mechanism of action of this drug?

Accepted Answer

NK1 antagonist

Answer

NK3 antagonist

Answer

NK1 agonist

Answer

NK2 agonist

Answer

NK2 antagonist

Question 10

Methotrexate use causes reduced synthesis of which of the following?

Accepted Answer

TMP

Answer

CMP

Answer

GMP

Answer

AMP

Answer

UMP

Antimicrobials — MCQs

Antimicrobials — MCQs

On this page

Practice by Chapter

Want unlimited practice?